Skip to main content Back to Top
Advertisement

10/2/2019

Ondansetron Hydrochloride Injection

Products Affected - Description

    • Zofran injection, Novartis, 2 mg/mL, 20 mL vial, 1 count, NDC 00173-0442-00 - discontinued
    • Ondansetron injection, AuroMedics, 2 mg/mL, 2 mL vial, 25 count, NDC 55150-0125-02
    • Ondansetron injection, AuroMedics, 2 mg/mL, 20 mL vial, 1 count, NDC 55150-0126-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 20 mL vial, 1 count, NDC 63323-0374-20
    • Ondansetron injection, Heritage, 2 mg/mL, 2 mL vial, 10 count, NDC 23155-0547-41 - discontinued
    • Ondansetron injection, Hikma, 2 mg/mL, 20 mL vial, 1 count, NDC 00143-9890-01
    • Ondansetron injection, Hikma, 2 mg/mL, 20 mL vial, 10 count, NDC 00143-9890-10
    • Ondansetron injection, Pfizer, 2 mg/mL, 2 mL iSecure syringe, 10 count, NDC 00409-1120-12
    • Ondansetron injection, Pfizer, 2 mg/mL, 20 mL vial, 1 count, NDC 00409-4759-01
    • Ondansetron injection, Sagent, 2 mg/mL, 2 mL vial, 25 count, NDC 25021-0777-02

Reason for the Shortage

    • Apotex has ondansetron injection available.
    • Athenex had ondansetron injection on shortage due to increased demand.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has ondansetron injection available.
    • Heritage had ondansetron on shortage due to increased demand. Heritage discontinued ondansetron 2 mg/mL 2 mL vials in 10 count in late-2018.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional refuses to provide availability information.
    • Pfizer has ondansetron injection on shortage due to manufacturing delays.
    • Sagent has ondansetron injection on shortage due to increased demand and manufacturing delays.
    • Novartis discontinued Zofran 20 mL vials in May 2018.

Available Products

    • Ondansetron injection, Apotex, 2 mg/mL, 2 mL vial, 25 count, NDC 60505-6130-05
    • Ondansetron injection, Athenex, 2 mg/mL, 2 mL vial, 25 count, NDC 70860-0776-02
    • Ondansetron injection, Athenex, 2 mg/mL, 20 mL vial, 1 count, NDC 70860-0777-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL prefilled syringe, 24 count, NDC 76045-0103-20
    • Ondansetron injection, Fresenius Kabi, 2 mg/mL, 2 mL vial, 25 count, NDC 63323-0373-02
    • Ondansetron injection, Heritage, 2 mg/mL, 2 mL vial, 25 count, NDC 23155-0547-42
    • Ondansetron injection, Heritage, 2 mg/mL, 20 mL vial, 1 count, NDC 23155-0549-31
    • Ondansetron injection, Hikma, 2 mg/mL, 2 mL vial, 25 count, NDC 00641-6078-25
    • Ondansetron injection, Pfizer, 2 mg/mL, 2 mL vial, 25 count, NDC 00409-4755-03
    • Ondansetron injection, Sagent, 2 mg/mL, 20 mL vial, 1 count, NDC 25021-0782-20

Estimated Resupply Dates

    • AuroMedics has ondansetron 2 mg/mL 2 mL vials and 20 mL vials on intermittent back order and the company is releasing supplies as they become available.
    • Fresenius Kabi has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date.
    • Hikma has ondansetron 2 mg/mL 20 mL vials in 1 count and 10 count on back order and the company cannot estimate a release date.
    • Pfizer has ondansetron 2 mg/mL 2 mL iSecure syringes on back order and the company estimates a release date of August 2020. The 2 mg/mL 20 mL vials are on back order and the company estimates a release date of November 2019.
    • Sagent has ondansetron 2 mg/mL 2 mL vials on back order and the company estimates a release date of October 2019.

Updated

Updated October 2, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins